196
Views
2
CrossRef citations to date
0
Altmetric
Letter to the Editor

Reply to Han et al.: impact on mortality of triple ICS/LABA/LAMA therapy in a population of COPD patients including also subjects with asthma-like profile

, , , & ORCID Icon
Pages 579-581 | Received 21 Oct 2020, Accepted 17 Dec 2020, Published online: 28 Dec 2020

References

  • Han MLK, Lipson DA, Singh D, et al. Reply to: “evaluating triple ICS/LABA/LAMA therapies for COPD patients: a network meta-analysis of ETHOS, KRONOS, IMPACT, and TRILOGY studies”. Expert Rev Respir Med. 2021;15(4): 1–2. doi:10.1080/17476348.2021.1865813
  • Calzetta L, Ritondo BL, de Marco P, et al. Evaluating triple ICS/LABA/LAMA therapies for COPD patients: a network meta-analysis of ETHOS, KRONOS, IMPACT, and TRILOGY studies. Expert Rev Respir Med. 2020;1–10. DOI:10.1080/17476348.2020.1816830.
  • Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378:1671–1680.
  • Suissa S. Mortality in IMPACT: confounded by asthma? Am J Respir Crit Care Med. 2020 May 12;202:772–773.
  • Wedzicha JA, Banerji D, Kostikas K. Single-inhaler triple versus dual therapy in patients with COPD. 10.1056/NEJMc1807380. N Engl J Med. 2018 Aug 9;379. DOI:10.1056/NEJMc1807380.
  • Suissa S, Drazen JM. Making sense of triple inhaled therapy for COPD. N Engl J Med. 2018 May 3;378(18):1723–1724.
  • Lipson DA, Dransfield MT, Han MK, et al. Reply to: mortality in IMPACT: confounded by asthma? Am J Respir Crit Care Med. 2020 May 12;202:773–774.
  • Lipson DA, Criner GJ, Lomas DA. The authors reply to: single-Inhaler triple versus dual therapy in patients with COPD. 10.1056/NEJMc1807380. N Engl J Med. 2018 Aug 9;378:1671–1680. .
  • Rogliani P, Ora J, Puxeddu E, et al. Airflow obstruction: is it asthma or is it COPD? Int J Chron Obstruct Pulmon Dis. 2016;11:3007.
  • Boulet L-P, Hanania NA. The many faces of asthma-chronic obstructive pulmonary disease overlap. Curr Opin Pulm Med. 2019;25(1):1–10.
  • Postma DS, Rabe KF. The asthma–COPD overlap syndrome. N Engl J Med. 2015;373(13):1241–1249 doi:10.1080/17476348.2021.1865813.
  • Pascoe S, Barnes N, Brusselle G, et al. Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. Lancet Respir Med. 2019;7(9):745–756.
  • Ferguson GT, Rabe KF, Martinez FJ, et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respir Med. 2018 Sep 14;6:747–758.
  • Rabe KF, Martinez FJ, Ferguson GT, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med. 2020;383:35–48.
  • Singh D, Papi A, Corradi M, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting beta2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet. 2016 Sep 03;388(10048):963–973.
  • van Valkenhoef G, Lu G, de Brock B, et al. Automating network meta-analysis. Res Synth Methods. 2012 Dec;3(4):285–299.
  • National NICE Institute for health and care excellence (NICE). Inhaled corticosteroid doses for NICE’s asthma guideline; 2018 [cited 2020 Nov 26]. Available from: http://www.nice.org.uk/guidance/ng80/resources/inhaled-corticosteroid-doses-pdf-4731528781
  • Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011 Apr;64(4):383–394.
  • Sullivan KM, Dean A, Soe MM. OpenEpi: a web-based epidemiologic and statistical calculator for public health. 433021. 2009;124(3):471.
  • Meinow B, Kåreholt I, Parker MG, et al. The effect of the duration of follow-up in mortality analysis: the temporal pattern of different predictors. J Gerontol B Psychol Sci Soc Sci. 2004;59(3):S181–S189.
  • Rosenthal GE. The role of pragmatic clinical trials in the evolution of learning health systems. Trans Am Clin Climatol Assoc. 2014;125:204.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.